Grifols SA - ADR - Level III

NASDAQ:GRFS 2:44:17 PM EDT

6.47

-0.12 (-1.75%)

Market Cap (Intraday)	1.66B
Current PE	9.19
Forward PE	7.34
2yr Forward PE	5.34

See more stats

Estimates Current Quarter

Revenue	$1.79 Billion
Adjusted EPS	$0.16

See more estimates

10-Day MA	$6.68
50-Day MA	$7.20
200-Day MA	$8.82

See more pivots

Grifols SA - ADR - Level III Stock, NASDAQ:GRFS

Avinguda de la Generalitat, 152-158, Parc de Negocis Can Sant Joan, Barcelona, Catalonia 08174

United States of America

Phone: +34.93.571.02.21

Number of Employees: 23744

http://www.grifols.com

Description

Grifols SA engages in the production of plasma derivatives. It operates through the following segments: Bioscience, Hospital, Diagnostic, Bio Supplies, and Others. The Bioscience Segment includes all activities related with products deriving from human plasma for therapeutic use. The Hospital Segment comprises of all non-biological pharmaceutical products and medical supplies manufactured by group companies earmarked for hospital pharmacy. The Diagnostic Segment deals with the marketing of diagnostic testing equipment, reagents, and other equipment. The Bio Supplies segment consists of all transactions related to biological products for non-therapeutic use. The Others segment focuses on the rendering of manufacturing services to third party companies. The company was founded by JosÃ?Â© Antonio Grifols Roig on November 18, 1940 and is headquartered in Barcelona, Spain.